Responsible for the Global Strategy of prescription Gastro portfolio (Normix, Clensia, Pentacol) & Onligol family (mix of OTC, food supplement and medical device products).

Helping affiliates to launch new products while implementing global marketing guidelines to develop current portfolio.

Management of Vascular (Vessel Due F®) and Gastro portfolio (Ateka®, Esoxx-ONE®, Flonorm®, Zir-Fos® & Zir-ComBi®).Lead the launch of Ateka®, Esoxx-ONE®, Flonorm® 400 & 550, Zir-Fos® NC & Zir-ComBi®.Lead the Business Development Strategy for Mexico through assessment of local & international products.Lead the Digital Transformation for the Mexican affiliate.Double digit on internal sales due to organic growth: +27.7% (2018), +23.6% (2019), +12.0% (2020), +36.5% (2021) and +28.7% (2022).

Management of Vascular (Vessel Due F®) and Gastro portfolio (Flonorm® & Zir-Fos®)Double digit on internal sales due to organic growth: +29.6% (2016) and +28.2% (2017)

Management of Gastro portfolio: gastrointestinal infections (Flonorm family) and symbiotic (Zir‐Fos).

Integrating the strengths of 6 products in a Gastroenterology portfolio: Samyr, Creon, Duspatalin, Dicetel, Ogastro & Duphalac.• Portfolio growth of 12.2% vs. 2013 (values).• Development of key opinion leaders (KOL) for the portfolio key products (Samyr, Creon & Duspatalin).

Management of irritable bowel syndrome –IBS– franchise (Dicetel / Duspatalin), hepatoprotector (SAMyr) and hormonal (Duphaston). After one year:• Duspatalin growth of 3.4% (units) in a flat market dominated by generics.• SAMyr growth of 3.2% (units) with the highest price in the category.• Duphaston relaunching (Solvay post-merger), achieving growth of 51.3% (units).

Management of Medix CNS portfolio: binge eating disorder (Esbelcaps), depression (Prepram) and insomnia (Cronocaps).• 2011 -> CNS Line sales objective exceeded with coverage of 109.6% (units) & 121% (values). First time since launching (2007) that the CNS Line achieves its objective.• 2012 -> CNS Line sales objective exceeded with coverage of 111.7% (units) & 110.9% (values). Profitability of the line exceeded by 51%.• 2012 vs. 2011 growth -> 12.6% (units) & 18.3% (values).Management of Novartis Pain portfolio due to a commercial agreement: epilepsy & neuropathic pain (Tegretol), myorelaxant (Sirdalud) and NSAID (Flotac).• 2012 -> Tegretol’s objective exceeded by 33.6%.Business Development: responsible to evaluate feasibility of new products for the line / company.

Management of the antihistaminic (Evastel family), gastroprokinetic (Eborix pediatric) and antitussive (Sekisan) products.

Management of Ferrer cardiovascular portfolio launching in Mexico.• Launched Remodulin, an orphan drug for Pulmonary Arterial Hypertension -PAH-.• Launched Omacor, the first prescription Omega-3 drug in the Mexican market for the treatment of hypertriglyceridemia.• Introduced Ferrer among key opinion leaders (KOL) & medical audiences of the cardiovascular area.• Developed feasibility analysis for new products.

Design, development and management of MSD Mexico Webpage’s contents. Development and implementation of interactive marketing strategies for all the promoted products.• Developed the e-Marketing strategic plan 2008-2009 which redefined the direction of MSD Mexico online activities.• Achieved a growth of 64.0% and 8.7% in MSD Website total visits during 2006 & 2007, respectively.

Increase prescriptions of called physicians to boost products’ sale.• Achieved a sales coverage 35% above objectives in 2001.

Development of operational procedures and equipment qualification in production and packaging lines. Training operational personnel in the use of new equipments and systems.• Was involved in a whole packaging line start up (IMA C-90) which increased 15% company’s packaging capacity.

Development of operational procedures and equipment qualification in production lines. Areas, systems, cleaning and production lines processes validation.• Was involved in a whole production and packaging line start up for a new product.